SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Hudson MM, Mulrooney DA, Bowers DC, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol. 2009; 27: 2405-2414.
  • 2
    Ralleigh G, Given-Wilson R. Breast cancer risk and possible screening strategies for young women following supradiaphragmatic irradiation for Hodgkin's disease. Clin Radiol. 2004; 59: 647-650.
  • 3
    Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007; 57: 75-89.
  • 4
    Children's Oncology Group (COG). COG website. Available at: www.survivorshipguidelines.org; 2008. Accessed July 22, 2009.
  • 5
    Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003; 97: 2397-2403.
  • 6
    Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin's disease treated with chest radiotherapy. J Clin Oncol. 2004; 22: 3139-3148.
  • 7
    Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007; 109: 1878-1886.
  • 8
    Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003; 21: 4386-4394.
  • 9
    Hodgson DC, MacKenzie R, Forde N, et al. Increased risk of clinically significant cardiac toxicity following modern treatment for Hodgkin's Disease. Eur J Haematol. 2004; 73: 21.
  • 10
    Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007; 99: 206-214.
  • 11
    van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994; 12: 312-325.
  • 12
    Jost L. Hodgkin's disease: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2007; 18( suppl 2): ii53-ii54.
  • 13
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Hodgkin Disease/Lymphoma, version 2. Fort Washington, Pa: NCCN; 2009.
  • 14
    Ng AK, Li S, Recklitis C, et al. Health practice in long-term survivors of Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2008; 71: 468-476.
  • 15
    Nathan PC, Greenberg ML, Ness KK, et al. Medical care in long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2008; 26: 4401-4409.
  • 16
    Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009; 301: 404-414.
  • 17
    Snyder CF, Earle CC, Herbert RJ, et al. Trends in follow-up and preventive care for colorectal cancer survivors. J Gen Intern Med. 2008; 23: 254-259.
  • 18
    Snyder CF, Frick KD, Kantsiper ME, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009; 27: 1054-1061.
  • 19
    JaakkimainenL, UpshurR, Klein-GeltinkJ, et al, eds. Primary Care in Ontario: ICES Atlas. Toronto, Ontario: Institute for Clinical Evaluative Sciences; 2006.
  • 20
    [No authors listed] NCCN practice guidelines for Hodgkin's disease. National Comprehensive Cancer Network. Oncology (Williston Park). 1999; 13: 78-110.
  • 21
    Hodgson DC, Pintilie M, Yun L, et al. Cardiovascular morbidity following modern treatment for Hodgkin lymphoma: age- and sex-specific estimates of risk in the doxorubicin era. Int J Radiat Oncol Biol Phys. 2008; 72: S122-S123.
  • 22
    Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008; 49: 1486-1493.
  • 23
    Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007; 25: 1489-1497.
  • 24
    Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol. 1997; 15: 1123-1130.
  • 25
    Radford JA, Eardley A, Woodman C, et al. Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ. 1997; 314: 343-346.
  • 26
    Dryver ET, Jernstrom H, Tompkins K, et al. Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer. 2003; 89: 482-486.
  • 27
    Guadagnolo BA, Punglia RS, Kuntz KM, et al. Cost-effectiveness analysis of computerized tomography in the routine follow-up of patients after primary treatment for Hodgkin's disease. J Clin Oncol. 2006; 24: 4116-4122.
  • 28
    Laupacis A, Przybysz R, Anne Keller A. CT and MRI scanning. In: TuJ, PinfoldS, McColganP, et al, eds. Access to Health Services in Ontario, 2nd ed. Toronto, Ontario: Institute for Clinical Evaluative Sciences; 2006.
  • 29
    Cancer Care Ontario. Cancer Quality Council of Ontario: Cancer Care Ontario, 2008. Available at: http://www.cancercare.on.ca/cms/One.aspx?portalId=14473&pageId=14840. Accessed July 22, 2009.
  • 30
    Ng AK, Bernardo MV, Weller E, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood. 2002; 100: 1989-1996.
  • 31
    Grunfeld E, Levine MN, Julian JA, et al. Randomized trial of long-term follow-up for early-stage breast cancer: a comparison of family physician versus specialist care. J Clin Oncol. 2006; 24: 848-855.
  • 32
    Oeffinger KC, Wallace WH. Barriers to follow-up care of survivors in the United States and the United Kingdom. Pediatr Blood Cancer. 2006; 46: 135-142.
  • 33
    Hutchings M, Eigtved AI, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol. 2004; 52: 19-32.
  • 34
    Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006; 47: 1326-1334.
  • 35
    Raanani P, Shasha Y, Perry C, et al. Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era? Ann Oncol. 2006; 17: 117-122.
  • 36
    Rigacci L, Castagnoli A, Dini C, et al. FDG-positron emission tomography in post treatment evaluation of residual mass in Hodgkin's lymphoma: long-term results. Oncol Rep. 2005; 14: 1209-1214.
  • 37
    Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006; 24: 5117-5124.
  • 38
    Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA. 2007; 297: 2762-2764.